A large study involving about 350,000 people in Britain reports that metformin use is associated with a lower risk of osteoarthritis affecting the knee and hip. Osteoarthritis is described as the “wear and tear” of joint cartilage and surrounding tissues. Across the study, metformin is reported to be linked to an approximately 24% reduction in the risk of developing knee and hip osteoarthritis. The reporting notes that metformin has been used since the 1950s, primarily as a treatment for diabetes. The articles describe the findings as potentially relevant to joint health, although the coverage does not provide additional details on how the study controls for other factors such as diabetes severity, weight, or overall health. No information is provided in the excerpts about whether the study is randomized or observational, the time frame of follow-up, or recommendations regarding who should take metformin. The key shared point across sources is the observed association between metformin and a reduced incidence of knee and hip osteoarthritis.